Enanta Pharmaceuticals Inc (ENTA): 7:01 pm AbbVie: Investigational chronic...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	2
Posts	283
Boards Moderated	0
Alias Born	08/25/2006

steveporsche

Re: None

Wednesday, 04/15/2015 11:29:22 PM

Wednesday, April 15, 2015 11:29:22 PM

7:01 pm AbbVie: Investigational chronic hepatitis C treatment granted priority review in Japan (ABBV) : Co announced that the Japanese Ministry of Health, Labour and Welfare (:MHLW) has granted priority review for its investigational, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir. This all-oral treatment is interferon (IFN) and ribavirin (RB.V)-free and will be dosed once daily. The MHLW grants priority review to certain medicines on the basis of clinical usefulness and severity of the disease, including diseases like hepatitis C, which affects approximately 1.5 to 2 million people in Japan. AbbVie's investigational hepatitis C treatment was submitted for marketing approval in Japan in February 2015. The New Drug Application is for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (:HCV) infection and is supported by the Phase 3 GIFT-I study in Japanese genotype 1b (GT1b) HCV patients.

http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#abbv